ELIGARD® (Leuprolide Acetate) | Support for Patients and Care Partners

Not an actual patient.

PATIENT AND CARE PARTNER RESOURCES

Your patients and their care partners have support every step of the way with these comprehensive programs from Tolmar

IncreMENtal is the ONLY habit-building program for patients with advanced prostate cancer

IncreMENtal provides personalized support for patients on androgen deprivation therapy and their care partners as they build a healthier lifestyle. IncreMENtal gives patients small, simple actions that add up over time to help overcome the challenges of prostate cancer treatment.

Fully online, self-guided courses have:

Easy-to-follow food, fitness, and mental health tips

Personal progress tracking to help set and keep goals

Comprehensive information in a simple, digestible format that is easy to absorb and implement

New weekly information to help change habits step by step

Learn more at IncreMENtalADT.com

IncreMENtal Nurse Brochure

IncreMENtal is the ONLY habit-building program for patients with advanced prostate cancer. The IncreMENtal Nurse Brochure helps nurses prepare their patients for the IncreMENtal program by providing information covered in the program along with sample lessons, how to get patients to adhere to habit building, and more.

Learn more at IncreMENtalADT.com.

Care Partner Corner supports care partners through the prostate cancer journey

Care Partner Corner is a comprehensive, easy-to-navigate resource designed for the care partners of patients with prostate cancer. This resource helps care partners feel informed, supported, and cared for throughout their loved one’s diagnosis and treatment journey.

At Care Partner Corner, care partners can find:

Easy-to-understand information about stages of prostate cancer, from localized to advanced

Downloadable resources to equip them with tools for treatment management and support their overall well-being

Access to supportive communities that can help  them connect with others going through similar experiences

Learn more at CarePartnerCorner.com

Tolmar Total Solutions can help your patients access ELIGARD

Tolmar Total Solutions is a comprehensive suite of reimbursement and patient assistance services dedicated to optimizing patient access to ELIGARD. We offer a full line of patient support services, including benefit verification; assistance with prior authorizations, appeals, and billing and coding inquiries; patient education materials; and our Patient Assistance Program (PAP).

Tools and resources for your patients & their care partners

Tolmar is here to support your patients & their care partners with the resources below

PROSTATE CANCER & YOU GUIDE

Provide patients with a comprehensive resource to help them navigate their way through prostate cancer treatment.

GETTING STARTED WITH ELIGARD guide

Give this guide to your patients so they know what they can expect with ELIGARD treatment.

PROSTATE CANCER 360 ROADMAP

Share the patient roadmap from PC360 with your patients to help them prepare for ADT and learn how to navigate their diagnosis.

Patient advocacy groups

We support patient organizations, national and local professional associations, and patient advocacy groups

American Urological Association 
(AUA)

Society of Urologic Oncology (SUO)

Veterans Prostate Cancer Awareness (VPCa)

Large Urology Group Practice Association (LUGPA)

Society of Urologic Nurses and Associates (SUNA)

American Society of Clinical Oncology (ASCO)

ZERO Prostate Cancer

Prostate Cancer Foundation

American Cancer Society

Get answers to frequently asked questions about ELIGARD

LHRH, luteinizing hormone-releasing hormone.

Reference: 1. Data on file. Tolmar Inc.; 2026.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.